Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A polyvalent vaccine for high-risk prostate patients: "are more antigens better?".
Slovin SF, Ragupathi G, Fernandez C, Diani M, Jefferson MP, Wilton A, Kelly WK, Morris M, Solit D, Clausen H, Livingston P, Scher HI. Slovin SF, et al. Cancer Immunol Immunother. 2007 Dec;56(12):1921-30. doi: 10.1007/s00262-007-0335-y. Epub 2007 Jul 10. Cancer Immunol Immunother. 2007. PMID: 17619878 Free PMC article. Clinical Trial.
HER-2 profiling and targeting in prostate carcinoma.
Morris MJ, Reuter VE, Kelly WK, Slovin SF, Kenneson K, Verbel D, Osman I, Scher HI. Morris MJ, et al. Among authors: slovin sf. Cancer. 2002 Feb 15;94(4):980-6. Cancer. 2002. PMID: 11920466 Free article. Clinical Trial.
Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D, Danishefsky S, Livingston P, Scher HI. Slovin SF, et al. Cancer Immunol Immunother. 2005 Jul;54(7):694-702. doi: 10.1007/s00262-004-0598-5. Epub 2005 Feb 22. Cancer Immunol Immunother. 2005. PMID: 15726361 Free PMC article. Clinical Trial.
A bivalent conjugate vaccine in the treatment of biochemically relapsed prostate cancer: a study of glycosylated MUC-2-KLH and Globo H-KLH conjugate vaccines given with the new semi-synthetic saponin immunological adjuvant GPI-0100 OR QS-21.
Slovin SF, Ragupathi G, Fernandez C, Jefferson MP, Diani M, Wilton AS, Powell S, Spassova M, Reis C, Clausen H, Danishefsky S, Livingston P, Scher HI. Slovin SF, et al. Vaccine. 2005 May 2;23(24):3114-22. doi: 10.1016/j.vaccine.2005.01.072. Vaccine. 2005. PMID: 15837210
177 results